Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Tyson Foods reported 2026 sales of $56.4 billion, a 3.6% increase driven by higher average sales prices and an additional fiscal week. Despite sales growth, net income attributable to Tyson decreased slightly to $453 million, impacted by significant restructuring charges, legal contingency accruals, and continued operating losses in the Beef segment.
Kevin Van Asdalan informed Montauk Renewables of his intention to resign as Chief Financial Officer, effective December 9, 2026. The company stated the departure is not due to any conflict or disagreement and expects to identify an interim CFO during the transition period.
Montauk Renewables reported Q3 2026 revenues of $50.2 million, a 10.9% increase year-over-year, though net income fell 58.9% to $2.1 million. The company announced it has executed a non-binding term sheet to amend its credit facility to borrow additional debt and address liquidity concerns, avoiding a previously anticipated going concern qualification. Additionally, the company plans to invest $15.0 million in enhancements at its Turkey, North Carolina facility to address feedstock moisture and syngas temperature issues limiting commercial production.
Creative Realities reported Q3 2026 revenue of $26.2 million, a significant increase from $10.5 million in the prior-year period, driven by the acquisition of Cineplex Digital Media and new contract wins. The company reported Adjusted EBITDA of $2.7 million and annualized recurring revenue (ARR) of $21.7 million. Management expects full-year 2026 revenue to exceed $100 million, supported by retail media deployments and stadium installations.
Term
Q3 2026
“We continue to set new records this year in terms of growth acceleration, business wins, and EBITDA expansion. We anticipate revenue exceeding $100 million in fiscal 2026, as the fourth quarter is expected to benefit from seasonal factors related to our retail media contracts as well as from the positive impact of recent awards and new customer installations.”
Rick Mills, Chief Executive Officer
“We focused on the balance sheet this quarter, using existing cash to pay down debt, provide increased financial flexibility, and reduce ongoing interest expense. Our talented staff and leadership successfully executed an operating strategy that is producing significant growth as we become a more nimble organization intent on achieving improved bottom line results and cash generation.”
Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.
Mara Holdings Signs $1.5B M&A Deal with Long Ridge Energy & Power LLC
MARA Holdings subsidiary MARA USA Corporation has commenced a $185 million private offering of senior secured notes to fund its previously announced $1.5 billion acquisition of Long Ridge Energy & Power LLC. The acquisition includes 100% of the membership interests in the target, which is the parent of Long Ridge Energy LLC. Proceeds will also be used to repay existing indebtedness and cover transaction fees.
Tyson Foods reported fourth quarter and fiscal year 2026 results, with annual sales increasing 3.6% to $56.4 billion. While GAAP operating income remained flat at $1.1 billion, adjusted EPS for the full year declined 17% to $3.44, reflecting a challenging operating environment despite growth in Prepared Foods and resilience in the Chicken segment.
“Our performance in fiscal 2026 reflects the strength of our diversified multiprotein model and our dedication to our customers and consumers. We’ll build on those strengths through investment in our brands, innovation and operating capabilities, while remaining focused on the returns those investments can deliver alongside market conditions.”
Jeff Schomburger, President and CEO of Tyson Foods
Edible Garden reported third quarter 2026 financial results, featuring a 14% revenue increase to $3.2 million and a significant gross margin expansion to 23.9%. The company highlighted strong growth in cut herb sales and secured a major private-label RTD protein beverage award from a large grocery retailer. Management noted that these improvements were achieved during the company's seasonally slowest quarter.
Term
Q3 2026
“Our third-quarter results reflect meaningful progress in strengthening our business.”
Jim Kras, Chief Executive Officer of Edible Garden
VIDA Global reported Q3 2026 financial results with revenue increasing 88% year-over-year to $0.33 million. The company highlighted the transition of its computer agents out of beta and the expansion of its go-to-market team and partnerships with ALLO Fiber and AVANT.
Term
Q3 2026
“In the third quarter, we believe we put the foundation in place to scale Vida’s AI workforce. Our computer agents came out of beta, so Vida’s AI employees now have the ability to do the work behind the conversation, not just the conversation. We built outcome-based billing, expanded our sales team, and signed partners including ALLO Fiber and AVANT.”
CareTrust REIT, Inc. has updated its investor presentation and made it available on the company's website. The filing was made under Item 7.01 (Regulation FD Disclosure) to provide current information to investors and analysts.
Joseph Todisco, CEO, bought 80,000 shares of CorMedix Inc. at $4.89 a share, worth $391K in total on Nov 13, 2026. Shares held after the trade: 854,749 (+10.3%).
Agape ATP Corp reported a significant decline in revenue to $40,079 for the nine months ended September 30, 2026, compared to $352,844 in the prior year. Despite the revenue drop, the net loss narrowed to $275,153 from $1,931,535, primarily due to a substantial $1.3 million foreign exchange gain and income from the disposal of discontinued operations.
ZW Data Action Technologies Inc. reported total assets of $10.68 million as of September 30, 2026, an increase from $9.68 million at the end of 2025. The company continues to navigate regulatory risks associated with the Holding Foreign Companies Accountable Act (HFCAA) due to its auditor's location in Hong Kong.
MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.
CNS Pharmaceuticals reported a net loss of $10.0 million for the nine months ended September 30, 2026, while significantly strengthening its cash position to $17.2 million following a $22.5 million private placement in May 2026. The company is currently pivoting its corporate strategy toward acquiring new therapeutic assets and exploring out-licensing opportunities for its legacy glioblastoma programs.
Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.
FitLife Brands reported a 39.5% increase in revenue for the nine months ended September 30, 2026, reaching $77.5 million compared to $55.5 million in the prior year. Net income for the nine-month period rose to $5.24 million, driven by organic growth and the impact of the Irwin acquisition, despite higher interest expenses and selling costs.
Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.
“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
The Macerich Company announced the acquisition of Oakridge Mall, a 1.1 million square foot super-regional retail center in San Jose, California, for approximately $250 million. The acquisition is funded through the partial settlement of 11 million shares of common stock previously sold on a forward basis in June 2026 at an initial forward price of $23.12 per share.
Prelude Therapeutics reported a net loss of $36.9 million for the nine months ended September 30, 2026, a significant improvement from the $83.0 million loss in the prior year period, driven by a decrease in R&D expenses and $15.9 million in recognized revenue. The company strengthened its balance sheet through a $90.0 million issuance of common stock and pre-funded warrants, ending the period with $142.4 million in total current assets.
MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.
Term
Q3 2026
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”
Chris Kroeger, Co-Founder and Chief Executive Officer
“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”
Chris Kroeger, Co-Founder and Chief Executive Officer
Xtend AI Robotics reported Q3 2026 revenue of $14.9 million, a 281% year-over-year increase, driven by its AI Robotics segment. The company ended the quarter with a fully funded backlog exceeding $100 million and $66.7 million in cash following its NYSE listing and business combination with JFB Construction.
Term
Q3 2026
“Our first quarter as a public company shows our strategy is working. Revenue nearly quadrupled, nine-month revenue has already passed all of 2025, and we ended the quarter with a fully funded backlog of more than $100 million. XTEND is not just another drone company. We are a Physical AI company”
Aviv Shapira, Co-Founder and Chief Executive Officer
Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”
Carole Ben-Maimon, M.D., Chief Executive Officer
“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”
Instil Bio, Inc. reported a net loss of $13.0 million for the nine months ended September 30, 2026, a significant reduction from the $63.5 million loss in the prior year period. The company is transitioning its strategy, having discontinued its lead product candidate AXN-2510 in January 2026, and is currently seeking to in-license or acquire new therapeutic candidates.
Amdocs Director La Vega Rafael De Buys $102K of Stock
La Vega Rafael De, Director, bought 2,297 shares of Amdocs Ltd at $44.51 a share, worth $102K in total on Nov 12, 2026. Shares held after the trade: 38,191 (+6.4%).
Sativus Tech Corp. reported a net loss of $539 thousand for the nine months ended September 30, 2026, compared to $923 thousand in the prior year. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $24.9 million and negative operating cash flows.
Venu Holding Corp reported total revenues of $14.09 million for the nine months ended September 30, 2026, a slight increase from $13.37 million in the prior year. The company experienced a significant net loss of $49.81 million during this period, driven by high general and administrative expenses and equity-based compensation. Total assets grew to $587.63 million, primarily due to a substantial increase in property and equipment related to amphitheater development.
Xtant Medical Holdings reported total assets of $75.2 million as of September 30, 2026, a decrease from $94.1 million at year-end 2025, primarily driven by a reduction in cash and the settlement of a $10.5 million note receivable. The company is currently undergoing a strategic review by its Board of Directors and recently expanded its product portfolio with the exclusive distribution of HEMOBLAST Bellows.
QVC Group, Inc. has emerged from Chapter 11 bankruptcy proceedings as of July 20, 2026, implementing a reorganization plan that includes approximately $1.3 billion in Takeback Debt and a $600 million Exit ABL Facility. The company reported 49,999,897 shares of common stock outstanding as of October 31, 2026, and is now operating under fresh start accounting which limits comparability to historical financial periods.
Barrel Energy Inc. reported a significant net loss of $1,518,216 for the nine months ended September 30, 2026, compared to a net income of $53,795 in the prior year period. The loss was primarily driven by a $1,056,653 change in the fair value of derivative liabilities and a substantial increase in operating expenses including consulting, marketing, and R&D.